Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study
P.F.R. Margarido1, V.R. Bagnoli1, Â. Maggio da Fonseca1, G.A.R. Maciel1, J.M. Soares Jr.1,*, É.A. D’Amico2, E.C. Baracat1
Show Less
1
Department of Obstetrics and Gynecology, São Paulo University
2
Coagulation Laboratory, Hematology Unit, General Hospital, Medical School, University of São Paulo, São Paulo (Brazil)
Clin. Exp. Obstet. Gynecol. 2011, 38(3), 232–235;
Published: 10 September 2011
Abstract
Objective: To evaluate thromboelastographic parameters and fibrinogen levels in women treated with transdermal 17β estradiol. Methods: 29 menopausal women with a history of venous thromboembolic disease were included. Nine patients composed the treatment (HT) group and 20 the control group. Coagulation was assessed by thromboelastography in samples of whole blood and plateletpoor plasma (PPP). The following thromboelastographic variables were measured: time for initial coagulation (R), blood clotting speed (K and the α angle), clot tensile strength (MA and G), global index of coagulation (CI) and fibrinolysis (LY30) and fibrinogen levels. Results: There were no differences in the other parameters comparing both groups. Fibrinogen levels showed a 13.77 ± 19.94% reduction in the HT group and a 5.51 ± 8.09% increase in the control group after 6 months. Conclusions: Our data suggested that transdermal estrogen may not increase blood coagulability, but that it reduces fibrinogen levels in HT women.
Keywords
Hormone therapy
Menopause
Venous thromboembolism
Blood coagulation
Fibrinogen